Avalo Therapeutics
AVTX
Avalo Therapeutics (AVTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$1.92
- EPS estimate
- −$1.40
- EPS surprise
- −36.93%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 7, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 7, 2025 | −$1.40 | −$1.92 | −36.93% | $0.00 | SEC |
| Q1 2025 | May 12, 2025 | −$1.33 | −$1.25 | +6.16% | $0.00 | SEC |
| Q4 2024 | Mar 20, 2025 | −$0.17 | −$2.30 | −1266.61% | $200,000.00 | SEC |
| Q3 2024 | Nov 7, 2024 | −$1.19 | −$2.83 | −137.82% | $249,000.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$6.70 | −$14.07 | −110.00% | $0.00 | SEC |
| Q1 2024 | May 13, 2024 | −$1.18 | −$141.00 | −11849.15% | $0.00 | SEC |
| Q4 2023 | Mar 29, 2024 | −$4.80 | −$10.10 | −110.42% | $574,000.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$264.00 | −$26.40 | +90.00% | $236,000.00 | SEC |
| Q2 2023 | Aug 3, 2023 | −$192.00 | −$141.60 | +26.25% | $643,000.00 | SEC |
| Q1 2023 | May 4, 2023 | −$232.80 | −$204.00 | +12.37% | $475,000.00 | SEC |
| Q4 2022 | Mar 29, 2023 | −$176.00 | −$237.60 | −35.00% | $901,000.00 | SEC |
| Q3 2022 | Nov 7, 2022 | −$210.60 | $81.60 | +138.75% | $14.9M | SEC |
| Q2 2022 | Aug 4, 2022 | −$424.80 | −$331.20 | +22.03% | $1.0M | SEC |
| Q1 2022 | May 5, 2022 | −$360.00 | −$576.00 | −60.00% | $1.2M | SEC |
| Q4 2021 | Mar 2, 2022 | −$426.24 | −$460.80 | −8.11% | $198,000.00 | SEC |
| Q3 2021 | Nov 9, 2021 | −$483.84 | −$489.60 | −1.19% | $1.4M | SEC |
| Q2 2021 | Aug 2, 2021 | −$480.00 | −$518.40 | −8.00% | $3.4M | SEC |
| Q1 2021 | May 13, 2021 | −$480.00 | −$921.60 | −92.00% | $473,000.00 | SEC |
| Q4 2020 | Mar 8, 2021 | −$432.00 | −$460.80 | −6.67% | $1.5M | SEC |
| Q3 2020 | Nov 9, 2020 | −$273.60 | −$460.80 | −68.42% | $1.1M | SEC |
Quarterly revenue
Frequently asked questions
When did Avalo Therapeutics (AVTX) last report earnings?
Avalo Therapeutics last reported on Aug 7, 2025, covering fiscal Q2 2025.
Did AVTX beat earnings estimates?
No. Avalo Therapeutics reported EPS of −$1.92 for Q2 2025 against a −$1.40 estimate — a 36.93% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.